EOLS Evolus, Inc.
USHealthcareAs of 2026-07-10 16:00
Why EOLS matters now
Evolus, Inc. (EOLS) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.61 with -3.50% on the session and $435.3M in market capitalization; recent performance reads 1-month +3.11% and YTD -0.30%.
The latest financial table shown here is Q1 2026, with revenue of $73.1M, net income of $-10.7M, and EPS of $-0.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.5%.
The latest indexable market news headline is "Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00; recent insider activity includes MOATAZEDI DAVID filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-15.02
P/S
1.45
EV/EBITDA
-39.32
DCF Value
$9.72
FCF Yield
-9.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
65.5%
Operating Margin
-9.6%
Net Margin
-14.4%
ROE
174.9%
ROA
-19.7%
ROIC
-18.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $73.1M | $-10.7M | $-0.16 |
| Q4 2025 | $90.3M | $130.0K | $0.00 |
| FY 2025 | $297.2M | $-51.6M | $-0.80 |
| Q3 2025 | $69.0M | $-15.7M | $-0.24 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$13.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
1.33
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.